Searching drug-like anti-cancer compound(s) based on G-Quadruplex Ligands

Current Pharmaceutical Design

Volumn 18, Issue 14, 2012, Pages 1973-1983

  Li, Qian ^a   Xiang, Jun Feng ^a   Zhang, Hong ^a,b   Tang, Ya Lin ^a  

^a PEKING UNIVERSITY   (China)

^b UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

Author keywords

Anti cancer; Drug screening; Drug like; G quadruplex; Medicinal chemistry; Telomerase; Telomere

Indexed keywords

ACRIDINE; ANTINEOPLASTIC AGENT; BRACO 19; CYANINE DYE; FLUORESCEIN; GUANINE QUADRUPLEX; NUCLEOLIN; PORPHYRIN DERIVATIVE; PROTEIN BCL 2; QUARFLOXIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; QUINOLONE DERIVATIVE; SINGLE STRANDED DNA; TELOMERASE; TELOMERASE REVERSE TRANSCRIPTASE; TELOMESTATIN; TMPYP4; TRIAZINE DERIVATIVE; UNCLASSIFIED DRUG;

ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; CANCER CELL; CELL PROLIFERATION; CLINICAL TRIAL (TOPIC); DNA DAMAGE; DOWN REGULATION; DRUG SCREENING; ELECTROSPRAY MASS SPECTROMETRY; FLUOROMETRY; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HYDROPHOBICITY; IN VITRO STUDY; IN VIVO STUDY; LYMPHOMA; MOLECULAR DOCKING; NUCLEAR MAGNETIC RESONANCE; ONCOGENE; PHASE 2 CLINICAL TRIAL (TOPIC); PLASMA HALF LIFE; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SOLID TUMOR; STREPTOMYCES; TUMOR GROWTH;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS, PHASE I AS TOPIC; DRUG DISCOVERY; DRUG SCREENING ASSAYS, ANTITUMOR; G-QUADRUPLEXES; HUMANS; LIGANDS;

EID: 84860211280     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161212799958369     Document Type: Review

References (130)

1. Sen D, Gilbert W. Formation of parallel four-stranded complexes by guanine-rich motifs in DNA and its implications for meiosis. Nature 1988; 334: 364-376.
2. Sundquist WI, Klug A. Telomeric DNA dimerizes by formation of guanine tetrads between hairpin loops. Nature 1989; 342: 825-829.
3. Zahler AM, Williamson JR, Cech TR, Prescott DM. Inhibition of telomerase by G-quartet DNA structures. Nature 1991; 350: 718-720.
4. Siddiqui-Jain A, Grand CL, Bearss DJ, Hurley LH. Direct evidence for a G-quadruplex in a promoter region and its targeting with a small molecule to repress c-MYC transcription. Proc Natl Acad Sci USA 2002; 99: 11593-11598.
5. Kumari S, Bugaut A, Huppert JL, Balasubramanian S. An RNA G-quadruplex in the 5' UTR of the NRAS proto-oncogene modulates translation. Nat Chem Biol 2007; 3: 218-221.
6. Bugaut A, Rodriguez R, Kumari S, Hsu ST, Balasubramanian S. Small molecule-mediated inhibition of translation by targeting a native RNA G-quadruplex. Org Biomol Chem 2010; 8: 2771-2776.
7. Todd AK, Haider SM, Parkinson GN, Neidle S. Sequence occurrence and structural uniqueness of a G-quadruplex in the human c-kit promoter. Nucleic Acids Res 2007; 35: 5799-5808.
8. Phan AT, Kuryavyi V, Burge S, Neidle S, Patel DJ. Structure of an unprecedented G-quadruplex scaffold in the human c-kit promoter. J Am Chem Soc 2007; 129: 4386-4392.
9. Fernando H, Reszka AP, Huppert J, et al. A conserved quadruplex motif located in a transcription activation site of the human c-kit oncogene. Biochemistry 2006; 45: 7854-7860.
10. Rankin S, Reszka AP, Huppert J, et al. Putative DNA quadruplex formation within the human c-kit oncogene. J Am Chem Soc 2005; 127: 10584-10589.
11. Kim NW, Piatyszek MA, Prowse KR, et al. Specific association of human telomerase activity with immortal cells and cancer. Science 1994; 266: 2011-2015.
12. Raymond E, Soria JC, Izbicka E, et al. DNA G-quadruplexes, telomere-specific proteins and telomere-associated enzymes as potential targets for new anticancer drugs. Invest New Drugs 2000; 18: 123-137.
13. Hurley LH, Wheelhouse RT, Sun D, et al. G-quadruplexes as targets for drug design. Pharmacol Ther 2000; 85: 141-158.
14. Mergny JL, Helene C. G-quadruplex DNA: a target for drug design. Nat Med 1998; 4: 1366-1367.
15. Fletcher TM, Sun D, Salazar M, Hurley LH. Effect of DNA secondary structure on human telomerase activity. Biochemistry 1998; 37: 5536-5541.
16. Cuesta J, Read MA, Neidle S. The design of G-quadruplex ligands as telomerase inhibitors. Mini Rev Med Chem 2003; 3: 11-21.
17. Souiden Y, Bouraoui A, Chaieb K, Mahdouani K. Telomeres and telomerase as targeted therapies in cancer treatment. Bull Cancer 2010; 97: 1087-1104.
18. Shalaby T, Hiyama E, Grotzer MA. Telomere maintenance as therapeutic target in embryonal tumours. Anticancer Agents Med Chem 2010; 10: 196-212.
19. Wong HM, Payet L, Huppert JL. Function and targeting of G-quadruplexes. Curr Opin Mol Ther 2009; 11: 146-155.
20. De Cian A, Lacroix L, Douarre C, et al. Targeting telomeres and telomerase. Biochimie 2008; 90: 131-155.
21. Riou JF, Morjani H, Trentesaux C. Telomeres and telomerase, new targets for anticancer chemotherapy. Ann Pharm Fr 2006; 64: 97-105.
22. Rezler EM, Bearss DJ, Hurley LH. Telomere inhibition and telomere disruption as processes for drug targeting. Annu Rev Pharmacol Toxicol 2003; 43: 359-379.
23. Burger AM, Dai F, Schultes CM, et al. The G-quadruplex-interactive molecule BRACO-19 inhibits tumor growth, consistent with telomere targeting and interference with telomerase function. Cancer Res 2005; 65: 1489-1496.
24. Cookson JC, Dai F, Smith V, et al. Pharmacodynamics of the G-quadruplex-stabilizing telomerase inhibitor 3,11-difluoro-6,8,13-trimethyl-8H-quino[4,3,2-kl]acridinium methosulfate (RHPS4) in vitro: activity in human tumor cells correlates with telomere length and can be enhanced, or antagonized, with cytotoxic agents. Mol Pharmacol 2005; 68: 1551-1558.
25. Duan W, Rangan A, Vankayalapati H, et al. Design and synthesis of fluoroquinophenoxazines that interact with human telomeric G-quadruplexes and their biological effects. Mol Cancer Ther 2001; 1: 103-120.
26. Gowan SM, Harrison JR, Patterson L, et al. A G-quadruplex-interactive potent small-molecule inhibitor of telomerase exhibiting in vitro and in vivo anti tumor activity. Mol Pharmacol 2002; 61: 1154-1162.
27. Monchaud D, Teulade-Fichou MP. A hitchhiker's guide to G-quadruplex ligands. Org Biomol Chem 2008; 6: 627-636.
28. Yang D, Okamoto K. Structural insights into G-quadruplexes: towards new anticancer drugs. Future Med Chem 2010; 2: 619-646.
29. Gunaratnam M, Swank S, Haider SM, et al. Targeting human gastrointestinal stromal tumor cells with a quadruplex-binding small molecule. J Med Chem 2009; 52: 3774-3783.
30. Grand CL, Han H, Munoz RM, et al. The cationic porphyrin TMPyP4 down-regulates c-MYC and human telomerase reverse transcriptase expression and inhibits tumor growth in vivo. Mol Cancer Ther 2002; 1: 565-573.
31. Thakur RK, Kumar P, Halder K, et al. Metastases suppressor NM23-H2 interaction with G-quadruplex DNA within c-MYC promoter nuclease hypersensitive element induces c-MYC expression. Nucleic Acids Res 2009; 37: 172-183.
32. Ofer N, Weisman-Shomer P, Shklover J, Fry M. The quadruplex r(CGG)n destabilizing cationic porphyrin TMPyP4 cooperates with hnRNPs to increase the translation efficiency of fragile X premutation mRNA. Nucleic Acids Res 2009; 37: 2712-2722.
33. Kim MY, Gleason-Guzman M, Izbicka E, Nishioka D, Hurley LH. The different biological effects of telomestatin and TMPyP4 can be attributed to their selectivity for interaction with intramolecular or intermolecular G-quadruplex structures. Cancer Res 2003; 63: 3247-3256.
34. Hurley LH, Von Hoff DD, Siddiqui-Jain A, Yang D. Drug targeting of the c-MYC promoter to repress gene expression via a G-quadruplex silencer element. Semin Oncol 2006; 33: 498-512.
35. Salvati E, Leonetti C, Rizzo A, et al. Telomere damage induced by the G-quadruplex ligand RHPS4 has an antitumor effect. J Clin Invest 2007; 117: 3236-3247.
36. Tauchi T, Shin-ya K, Sashida G, et al. Telomerase inhibition with a novel G-quadruplex-interactive agent, telomestatin: in vitro and in vivo studies in acute leukemia. Oncogene 2006; 25: 5719-5725.
37. Bates P, Mergny JL, Yang D. Quartets in G-major. The First International Meeting on Quadruplex DNA. EMBO Rep 2007; 8: 1003-1010.
38. Wilson WD, Sugiyama H. First International Meeting on Quadruplex DNA. ACS Chem Biol 2007; 2: 589-594.
39. Shafer RH. Stability and structure of model DNA triplexes and quadruplexes and their interactions with small ligands. Prog Nucleic Acid Res Mol Biol 1998; 59: 55-94.
40. Fan HY, Shek YL, Amiri A, et al. Volumetric characterization of sodium-induced G-quadruplex formation. J Am Chem Soc 2011; 133: 4518-4526.
41. Chen SB, Tan JH, Ou TM, et al. Pharmacophore-based discovery of triaryl-substituted imidazole as new telomeric G-quadruplex ligand. Bioorg Med Chem Lett 2011; 21: 1004-1009.
42. Hou JQ, Chen SB, Tan JH, et al. New insights into the structures of ligand-quadruplex complexes from molecular dynamics simulations. J Phys Chem B 2010; 114: 15301-15310.
43. Bazzicalupi C, Chioccioli M, Sissi C, et al. Modeling and biological investigations of an unusual behavior of novel synthesized acridine-based polyamine ligands in the binding of double helix and G-quadruplex DNA. ChemMedChem 2010; 5: 1995-2005.
44. Li MH, Luo Q, Xue XG, Li ZS. Molecular dynamics studies of the 3D structure and planar ligand binding of a quadruplex dimer. J Mol Model 2011; 17: 515-526.
45. Li MH, Luo Q, Li ZS. Molecular dynamics study on the interactions of porphyrin with two antiparallel human telomeric quadruplexes. J Phys Chem B 2010; 114: 6216-6224.
46. Alcaro S, Artese A, Costa G, et al. Conformational studies and solvent-accessible surface area analysis of known selective DNA G-Quadruplex binders. Biochimie 2011; 93: 1267-1274.
47. Zhou Q, Li L, Xiang J, Sun H, Tang Y. Fast screening and structural elucidation of G-quadruplex ligands from a mixture via G-quadruplex recognition and NMR methods. Biochimie 2009; 91: 304-308.
48. Zhou Q, Li L, Xiang J, et al. Screening potential antitumor agents from natural plant extracts by G-quadruplex recognition and NMR methods. Angew Chem Int Ed Engl 2008; 47: 5590-5592.
49. Largy E, Hamon F, Teulade-Fichou MP. Development of a high-throughput G4-FID assay for screening and evaluation of small molecules binding quadruplex nucleic acid structures. Anal Bioanal Chem 2011; 400: 3419-3427.
50. Casagrande V, Salvati E, Alvino A, et al. N-cyclic bay-substituted perylene G-quadruplex ligands have selective antiproliferative effects on cancer cells and induce telomere damage. J Med Chem 2011; 54: 1140-1156.
51. Lacroix L, Seosse A, Mergny JL. Fluorescence-based duplex-quadruplex competition test to screen for telomerase RNA quadruplex ligands. Nucleic Acids Res 2011; 39: e21.
52. Redman JE, Ladame S, Reszka AP, Neidle S, Balasubramanian S. Discovery of G-quadruplex stabilizing ligands through direct ELISA of a one-bead-one-compound library. Org Biomol Chem 2006; 4: 4364-4369.
53. Tran PL, Largy E, Hamon F, Teulade-Fichou MP, Mergny JL. Fluorescence intercalator displacement assay for screening G4 ligands towards a variety of G-quadruplex structures. Biochimie 2011; 93: 1288-1296.
54. Ragazzon P, Chaires JB. Use of competition dialysis in the discovery of G-quadruplex selective ligands. Methods 2007; 43: 313-323.
55. Brodbelt JS. Evaluation of DNA/Ligand interactions by electrospray ionization mass spectrometry. Annu Rev Anal Chem (Palo Alto Calif) 2010; 3: 67-87.
56. Han X, Li C, Mosher MD, et al. Design, synthesis and biological evaluation of a novel class of anticancer agents: anthracenyliso-xazole lexitropsin conjugates. Bioorg Med Chem 2009; 17: 1671-1680.
57. Casagrande V, Alvino A, Bianco A, Ortaggi G, Franceschin M. Study of binding affinity and selectivity of perylene and coronene derivatives towards duplex and quadruplex DNA by ESI-MS. J Mass Spectrom 2009; 44: 530-540.
58. Han H, Hurley LH. G-quadruplex DNA: a potential target for anti-cancer drug design. Trends Pharmacol Sci 2000; 21: 136-142.
59. Jiang YL, Liu ZP. Metallo-organic G-quadruplex ligands in anticancer drug design. Mini Rev Med Chem 2010; 10: 726-736.
60. Nielsen MC, Ulven T. Macrocyclic G-quadruplex ligands. Curr Med Chem 2010; 17: 3438-3448.
61. Tan JH, Gu LQ, Wu JY. Design of selective G-quadruplex ligands as potential anticancer agents. Mini Rev Med Chem 2008; 8: 1163-1178.
62. Sun D, Thompson B, Cathers BE, et al. Inhibition of human telomerase by a G-quadruplex-interactive compound. J Med Chem 1997; 40: 2113-2116.
63. Brooks TA, Hurley LH. Targeting MYC Expression through G-Quadruplexes. Genes Cancer 2010; 1: 641-649.
64. Izbicka E, Wheelhouse RT, Raymond E, et al. Effects of cationic porphyrins as G-quadruplex interactive agents in human tumor cells. Cancer Res 1999; 59: 639-644.
65. Shi DF, Wheelhouse RT, Sun D, Hurley LH. Quadruplex-interactive agents as telomerase inhibitors: synthesis of porphyrins and structure-activity relationship for the inhibition of telomerase. J Med Chem 2001; 44: 4509-4523.
66. Lauhon CT, Szostak JW. RNA aptamers that bind flavin and nicotinamide redox cofactors. J Am Chem Soc 1995; 117: 1246-1257.
67. Bejugam M, Sewitz S, Shirude PS, et al. Trisubstituted isoallo-xazines as a new class of G-quadruplex binding ligands: small molecule regulation of c-kit oncogene expression. J Am Chem Soc 2007; 129: 12926-12927.
68. Wang XD, Ou TM, Lu YJ, et al. Turning off transcription of the bcl-2 gene by stabilizing the bcl-2 promoter quadruplex with quindoline derivatives. J Med Chem 2010; 53: 4390-4398.
69. Zhou JL, Lu YJ, Ou TM, et al. Synthesis and evaluation of quindoline derivatives as G-quadruplex inducing and stabilizing ligands and potential inhibitors of telomerase. J Med Chem 2005; 48: 7315-7321.
70. Guyen B, Schultes CM, Hazel P, Mann J, Neidle S. Synthesis and evaluation of analogues of 10H-indolo[3,2-b]quinoline as G-quadruplex stabilising ligands and potential inhibitors of the enzyme telomerase. Org Biomol Chem 2004; 2: 981-988.
71. Heald RA, Modi C, Cookson JC, et al. Antitumor polycyclic acridines. 8.(1) Synthesis and telomerase-inhibitory activity of methylated pentacyclic acridinium salts. J Med Chem 2002; 45: 590-597.
72. Mergny JL, Lacroix L, Teulade-Fichou MP, et al. Telomerase inhibitors based on quadruplex ligands selected by a fluorescence assay. Proc Natl Acad Sci USA 2001; 98: 3062-3067.
73. Micheli E, D'Ambrosio D, Franceschin M, Savino M. Water soluble cationic perylene derivatives as possible telomerase inhibitors: the search for selective G-quadruplex targeting. Mini Rev Med Chem 2009; 9: 1622-1632.
74. Tauchi T, Shin-Ya K, Sashida G, et al. Activity of a novel G-quadruplex-interactive telomerase inhibitor, telomestatin (SOT-095), against human leukemia cells: involvement of ATM-dependent DNA damage response pathways. Oncogene 2003; 22: 5338-5347.
75. Doi T, Shibata K, Yoshida M, et al. (S)-stereoisomer of telomestatin as a potent G-quadruplex binder and telomerase inhibitor. Org Biomol Chem 2011; 9: 387-393.
76. Cocco MJ, Hanakahi LA, Huber MD, Maizels N. Specific interactions of distamycin with G-quadruplex DNA. Nucleic Acids Res 2003; 31: 2944-2951.
77. Gomez D, Aouali N, Renaud A, et al. Resistance to senescence induction and telomere shortening by a G-quadruplex ligand inhibitor of telomerase. Cancer Res 2003; 63: 6149-6153.
78. De Cian A, Delemos E, Mergny JL, Teulade-Fichou MP, Monchaud D. Highly efficient G-quadruplex recognition by bisquinolinium compounds. J Am Chem Soc 2007; 129: 1856-1857.
79. Yang Q, Xiang J, Yang S, et al. Verification of specific G-quadruplex structure by using a novel cyanine dye supramolecular assembly: II. The binding characterization with specific intramolecular G-quadruplex and the recognizing mechanism. Nucleic Acids Res 2010; 38: 1022-1033.
80. Yang Q, Xiang J, Yang S, et al. Verification of specific G-quadruplex structure by using a novel cyanine dye supra molecular assembly: I. recognizing mixed G-quadruplex in human telomeres. Chem Commun (Camb) 2009;1103-1105.
81. Yang Q, Xiang JF, Yang S, et al. Verification of intra molecular hybrid/parallel g-quadruplex structure under physiological conditions using novel cyanine dye H-aggregates: both in solution and on Au film. Anal Chem 2010; 82: 9135-9137.
82. Sun H, Tang Y, Xiang J, et al. Spectroscopic studies of the interaction between quercetin and G-quadruplex DNA. Bioorg Med Chem Lett 2006; 16: 3586-3589.
83. Sun H, Xiang J, Tang Y, Xu G. Regulation and recognization of the extended G-quadruplex by rutin. Biochem Biophys Res Commun 2007; 352: 942-946.
84. Yang S, Xiang J, Yang Q, et al. Distinct G-quadruplex structures of human telomeric DNA formed by the induction of sanguinarine and nitidine under salt-deficient condition. Fitoterapia 2010; 81: 1026-1032.
85. Li Q, Xiang J, Li X, et al. Stabilizing parallel G-quadruplex DNA by a new class of ligands: two non-planar alkaloids through interaction in lateral grooves. Biochimie 2009; 91: 811-819.
86. Brassart B, Gomez D, De Cian A, et al. A new steroid derivative stabilizes g-quadruplexes and induces telomere uncapping in human tumor cells. Mol Pharmacol 2007; 72: 631-640.
87. Sun H, Zhou Q, Xiang J, Tang Y. Polyethylenimine effectively induces, stabilizes, and regulates intramolecular G-quadruplexes. Bioorg Med Chem Lett 2009; 19: 4669-4672.
88. Zhang XF, Xiang JF, Tian MY, et al. Formation of an intra molecular G-quadruplex of human telomere induced by poly(L-lysine) under salt-deficient conditions. J Phys Chem B 2009; 113: 7662-7667.
89. Sun H, Xiang J, Liu Y, et al. A stabilizing and denaturing dual-effect for natural polyamines interacting with G-quadruplexes depending on concentration. Biochimie 2011; 93: 1351-1356.
90. Zhang H, Xiang JF, Hu HY, et al. Stabilizing G-quadruplex DNA by a scissors-shaped binaphthyl derivative through the entangling mode: cooperation of binaphthylene and the ethoxy chain. Biochemistry 2010; 49: 10351-10353.
91. Martino L, Virno A, Pagano B, et al. Structural and thermodynamic studies of the interaction of distamycin A with the parallel quadruplex structure [d(TGGGGT)]4. J Am Chem Soc 2007; 129: 16048-16056.
92. Phatak P, Cookson JC, Dai F, et al. Telomere uncapping by the G-quadruplex ligand RHPS4 inhibits clonogenic tumour cell growth in vitro and in vivo consistent with a cancer stem cell targeting mechanism. Br J Cancer 2007; 96: 1223-1233.
93. Martins C, Gunaratnam M, Stuart J, et al. Structure-based design of benzylamino-acridine compounds as G-quadruplex DNA telomere targeting agents. Bioorg Med Chem Lett 2007; 17: 2293-2308.
94. Drygin D, Siddiqui-Jain A, O'Brien S, et al. Anticancer activity of CX-3543: a direct inhibitor of rRNA biogenesis. Cancer Res 2009; 69: 7653-7661.
95. Bayes M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol 2007; 29: 53-71.
96. Bates PJ, Laber DA, Miller DM, Thomas SD, Trent JO. Discovery and development of the G-rich oligonucleotide AS1411 as a novel treatment for cancer. Exp Mol Pathol 2009; 86: 151-164.
97. Soundararajan S, Chen W, Spicer EK, Courtenay-Luck N, Fernandes DJ. The nucleolin targeting aptamer AS1411 destabilizes Bcl-2 messenger RNA in human breast cancer cells. Cancer Res 2008; 68: 2358-2365.
98. Teng Y, Girvan AC, Casson LK, et al. AS1411 alters the localization of a complex containing protein arginine methyltransferase 5 and nucleolin. Cancer Res 2007; 67: 10491-10500.
99. Cosconati S, Marinelli L, Trotta R, et al. Tandem application of virtual screening and NMR experiments in the discovery of brand new DNA quadruplex groove binders. J Am Chem Soc 2009; 131: 16336-16337.
100. Darby RA, Sollogoub M, McKeen C, et al. High throughput measurement of duplex, triplex and quadruplex melting curves using molecular beacons and a LightCycler. Nucleic Acids Res 2002; 30: e39.
101. Rosu F, De Pauw E, Gabelica V. Electrospray mass spectrometry to study drug-nucleic acids interactions. Biochimie 2008; 90: 1074-1087.
102. Hofstadler SA, Griffey RH. Analysis of noncovalent complexes of DNA and RNA by mass spectrometry. Chem Rev 2001; 101: 377-390.
103. Beck JL, Colgrave ML, Ralph SF, Sheil MM. Electrospray ionization mass spectrometry of oligonucleotide complexes with drugs, metals, and proteins. Mass Spectrom Rev 2001; 20: 61-87.
104. David WM, Brodbelt J, Kerwin SM, Thomas PW. Investigation of quadruplex oligonucleotide-drug interactions by electrospray ionization mass spectrometry. Anal Chem 2002; 74: 2029-2033.
105. Mazzitelli CL, Brodbelt JS, Kern JT, Rodriguez M, Kerwin SM. Evaluation of binding of perylene diimide and benzannulated perylene diimide ligands to DNA by electrospray ionization mass spectrometry. J Am Soc Mass Spectrom 2006; 17: 593-604.
106. Yamakuchi M, Nakata M, Kawahara K, Kitajima I, Maruyama I. New quinolones, ofloxacin and levofloxacin, inhibit telomerase activity in transitional cell carcinoma cell lines. Cancer Lett 1997; 119: 213-219.
107. Zeng Q, Kwok Y, Kerwin SM, Mangold G, Hurley LH. Design of new topoisomerase II inhibitors based upon a quinobenzoxazine self-assembly model. J Med Chem 1998; 41: 4273-4278.
108. Shin-ya K, Wierzba K, Matsuo K, et al. Telomestatin, a novel telomerase inhibitor from Streptomyces anulatus. J Am Chem Soc 2001; 123: 1262-1263.
109. Kim MY, Vankayalapati H, Shin-Ya K, Wierzba K, Hurley LH. Telomestatin, a potent telomerase inhibitor that interacts quite specifically with the human telomeric intramolecular g-quadruplex. J Am Chem Soc 2002; 124: 2098-2109.
110. Rezler EM, Seenisamy J, Bashyam S, et al. Telomestatin and diseleno sapphyrin bind selectively to two different forms of the human telomeric G-quadruplex structure. J Am Chem Soc 2005; 127: 9439-9447.
111. Seenisamy J, Bashyam S, Gokhale V, et al. Design and synthesis of an expanded porphyrin that has selectivity for the c-MYC G-quadruplex structure. J Am Chem Soc 2005; 127: 2944-2959.
112. Grootenhuis PD, Roe DC, Kollman PA, Kuntz ID. Finding potential DNA-binding compounds by using molecular shape. J Comput Aided Mol Des 1994; 8: 731-750.
113. Liu ZR, Rill RL. N,N'-bis[3,3'-(dimethylamino)propylamine]-3,4,9, 10-perylenetetracarboxylic diimide, a dicationic perylene dye for rapid precipitation and quantitation of trace amounts of DNA. Anal Biochem 1996; 236: 139-145.
114. Kerwin SM. G-Quadruplex DNA as a target for drug design. Curr Pharm Des 2000; 6: 441-478.
115. Fedoroff OY, Salazar M, Han H, et al. NMR-Based model of a telomerase-inhibiting compound bound to G-quadruplex DNA. Biochemistry 1998; 37: 12367-12374.
116. Han H, Cliff CL, Hurley LH. Accelerated assembly of G-quadruplex structures by a small molecule. Biochemistry 1999; 38: 6981-6986.
117. Kern JT, Thomas PW, Kerwin SM. The relationship between ligand aggregation and G-quadruplex DNA selectivity in a series of 3,4,9,10-perylenetetracarboxylic acid diimides. Biochemistry 2002; 41: 11379-11389.
118. Kern JT, Kerwin SM. The aggregation and G-quadruplex DNA selectivity of charged 3,4,9,10-perylenetetracarboxylic acid diimides. Bioorg Med Chem Lett 2002; 12: 3395-3408.
119. Gibbs EJ, Pasternack RF. Interaction of porphyrins and metalloporphyrins with nucleic acids. Semin Hematol 1989; 26: 77-85.
120. Lipscomb LA, Zhou FX, Presnell SR, et al. Structure of DNA-porphyrin complex. Biochemistry 1996; 35: 2818-2823.
121. Li Y, Geyer CR, Sen D. Recognition of anionic porphyrins by DNA aptamers. Biochemistry 1996; 35: 6911-6922.
122. Arthanari H, Basu S, Kawano TL, Bolton PH. Fluorescent dyes specific for quadruplex DNA. Nucleic Acids Res 1998; 26: 3724-3738.
123. Wheelhouse RT, Sun DK, Han HY, Han FXG, Hurley LH. Cationic porphyrins as telomerase inhibitors: the interaction of tetra-(N-methyl-4-pyridyl)porphine with quadruplex DNA. J Am Chem Soc 1998; 120: 3261-3262.
124. Han H, Langley DR, Rangan A, Hurley LH. Selective interactions of cationic porphyrins with G-quadruplex structures. J Am Chem Soc 2001; 123: 8902-9013.
125. Ren J, Chaires JB. Sequence and structural selectivity of nucleic acid binding ligands. Biochemistry 1999; 38: 16067-16075.
126. Wang P, Ren L, He H, et al. A phenol quaternary ammonium porphyrin as a potent telomerase inhibitor by selective interaction with quadruplex DNA. Chembiochem 2006; 7: 1155-1159.
127. Evans SE, Mendez MA, Turner KB, et al. End-stacking of copper cationic porphyrins on parallel-stranded guanine quadruplexes. J Biol Inorg Chem 2007; 12: 1235-1249.
128. Keating LR, Szalai VA. Parallel-stranded guanine quadruplex interactions with a copper cationic porphyrin. Biochemistry 2004; 43: 15891-15900.
129. Pan J, Zhang S. Interaction between cationic zinc porphyrin and lead ion induced telomeric guanine quadruplexes: evidence for end-stacking. J Biol Inorg Chem 2009; 14: 401-407.
130. Dixon IM, Lopez F, Tejera AM, et al. A G-quadruplex ligand with 10000-fold selectivity over duplex DNA. J Am Chem Soc 2007; 129: 1502-1503.